Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/04/10/2860973/0/en/Aprea-Therapeutics-Announces-Presentations-on-its-Next-Generation-WEE1-Inhibitor-APR-1051-and-A-Novel-Macrocyclic-ATR-Inhibitor-ATRN-119-at-AACR-Annual-Meeting-2024.html
https://www.globenewswire.com/news-release/2024/03/26/2852263/0/en/Aprea-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Provides-a-Business-Update.html
https://www.globenewswire.com//news-release/2024/03/11/2843776/0/en/Aprea-Therapeutics-Announces-Private-Placement-Financing-of-up-to-34-0-Million.html
https://www.globenewswire.com//news-release/2024/03/11/2843764/0/en/Aprea-Therapeutics-Announces-FDA-Clearance-of-IND-for-APR-1051-its-Next-Generation-WEE1-Kinase-Inhibitor-for-Cyclin-E-Overexpressing-Cancers.html
https://www.globenewswire.com//news-release/2024/03/05/2840965/0/en/Aprea-Therapeutics-Announces-Acceptance-of-Abstracts-at-American-Association-of-Cancer-Research-Annual-Meeting-2024.html
https://www.globenewswire.com//news-release/2024/02/06/2824296/0/en/Aprea-Therapeutics-Announces-Submission-of-IND-Application-for-APR-1051-a-Next-Generation-WEE1-Kinase-Inhibitor.html
https://www.globenewswire.com/news-release/2024/01/30/2819921/0/en/Aprea-Therapeutics-to-Present-at-DDR-Inhibitors-Summit-2024.html
https://www.globenewswire.com//news-release/2024/01/04/2804314/0/en/Aprea-Therapeutics-Provides-Corporate-Update-and-Announces-Development-Plans-for-2024.html
https://www.globenewswire.com//news-release/2023/11/09/2777790/0/en/Aprea-Therapeutics-Reports-Third-Quarter-2023-Financial-Results-and-Provides-a-Business-Update.html
https://www.globenewswire.com//news-release/2023/10/24/2765578/0/en/Aprea-Therapeutics-to-Host-a-Key-Opinion-Leader-KOL-Event-on-its-Synthetic-Lethality-SL-and-DNA-Damage-Response-DDR-Pathways.html